Formoterol Fumarate: Inke’s Flagship API for Respiratory Health

Every second, hundreds of people around the world take a life-changing breath—often supported by inhalation therapies containing Formoterol Fumarate. At Inke, we are proud to be part of this critical moment, helping improve respiratory health through science, precision and care.

Formoterol Fumarate Dihydrate is a long-acting bronchodilator widely used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). By relaxing the muscles around the airways, it helps patients breathe more easily and enhances their quality of life. Inke has been producing this key active pharmaceutical ingredient (API) since 1998, offering both micronized and non-micronized forms.

Our European-based manufacturing facility is equipped for large-scale production and provides strategic control over key raw materials. This ensures supply security and allows us to offer a consistently high-quality API to our global partners.

Key advantages of partnering with Inke for Formoterol Fumarate include:

• Ready-to-use micronized API with tight particle size distribution (PSD) control

• High purity levels and consistently low residual solvents

• Robust regulatory support, including a comprehensive portfolio of global DMFs (CEP, US-DMF, JP-DMF, KR-DMF, CN-DMF, CA-DMF, ZA-DMF, and others)

• Fast track to market with full compliance support

• A team with over 25 years of expertise in inhalation APIs and respiratory formulation requirements

Since 2016, Inke has invested significantly in advanced micronization technologies, reinforcing our leadership in respiratory API manufacturing. Through continuous innovation, technical excellence, and collaborative partnerships, we remain committed to supporting the development of effective inhalation therapies around the world.